文献速递认知障碍与谵妄多重用药

阿尔茨海默病患者中抗多巴胺能-抗帕金森药物的处方级联现象

Antidopaminergic-Antiparkinsonian Medication Prescribing Cascade in Persons with Alzheimer's Disease.
PubMed 文献 · J Am Geriatr Soc · 2021-01-11

本研究利用美国两个大型行政索赔数据库,纳入121,538例阿尔茨海默病患者,评估抗多巴胺能药物(抗精神病药/甲氧氯普胺)使用后8至365天内启动抗帕金森药物的处方级联比例。在4,534例新使用抗精神病药/甲氧氯普胺的患者中,仅36例(0.8%)后续新使用抗帕金森药物。研究认为该高优先级处方级联的实际比例较低。

要点

  • 阿尔茨海默病患者中新使用抗精神病药/甲氧氯普胺后,后续启动抗帕金森药物的比例为0.8%。
  • 研究队列平均年龄79.5岁,平均用药9.2种,提示多重用药负担重。
  • 该处方级联虽被视为高优先级,但实际发生比例低,仍需系统级干预保障用药安全。

核心结论

  • 在阿尔茨海默病患者中,抗多巴胺能-抗帕金森药物处方级联的比例为0.8%,虽然该级联被广泛视为高优先级问题,但实际比例较低。

研究设计与样本

  • 研究基于美国两个大型行政索赔数据库,纳入2017年1月1日时年龄≥50岁、在队列入口日前365天内或当日至少1天配取阿尔茨海默病治疗药物且具有医疗和药房覆盖的患者,排除近期机构居住者。
  • 共纳入121,538例阿尔茨海默病患者,其中约62%为女性,平均年龄79.5岁(SD ± 8.6),平均配药数量9.2种(SD ± 4.9)。

主要发现

  • 在队列入口后183天内新使用抗精神病药/甲氧氯普胺的患者共4,534例,其中36例在8至365天内后续新使用抗帕金森药物,比例为0.8%。

关键数值与推荐

  • 新发抗多巴胺能药物(抗精神病药/甲氧氯普胺)使用定义为队列入口后183天内;后续新发抗帕金森药物使用定义为8至365天内。

临床怎么用

  • 临床医生在阿尔茨海默病患者中处方抗精神病药或甲氧氯普胺时,仍应警惕后续启动抗帕金森药物的处方级联,但本研究提示其实际比例较低,可据此评估系统级干预的优先级。

局限性

  • 研究基于行政索赔数据库,可能受编码准确性、未纳入临床细节及仅限美国人群等因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Persons living with Alzheimer's disease (AD) may be at increased risk for prescribing cascades due to greater multimorbidity, polypharmacy, and the need for more complex care. Our objective was to assess the proportion of the antidopaminergic-antiparkinsonian medication prescribing cascades among persons living with Alzheimer's disease. SETTING: Two large administrative claims databases in the United States. PARTICIPANTS: We identified patients aged ≥50 on January 1, 2017, who were dispensed a drug used to treat Alzheimer's disease for at least 1 day in the 365 days prior to or on cohort entry date and who had medical and pharmacy coverage in the 365 days prior to the cohort entry date. We excluded individuals with a recent institutional stay. We identified incident antidopaminergic (antipsychotic/metoclopramide) use in the 183 days following cohort entry and identified subsequent incident antiparkinsonian drug use within 8 to 365 days. RESULTS: There were 121,538 patients with Alzheimer's disease eligible for inclusion. Approximately 62% were women with a mean age of 79.5 (SD ± 8.6). The mean number of drugs dispensed was 9.2 (SD ± 4.9). There were 36 incident antiparkinsonian users among 4,534 incident antipsychotic/metoclopramide users (0.8%). CONCLUSION: We determined that the proportion of antidopaminergic-antiparkinsonian medication prescribing cascades, widely considered as high-priority, was low. Our approach can be used to assess the proportion of prescribing cascades in populations considered to be at high risk and to prioritize system-level interventional efforts to improve medication safety in these patients.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Singh S, Cocoros NM, Haynes K, et al. Antidopaminergic-Antiparkinsonian Medication Prescribing Cascade in Persons with Alzheimer's Disease. J Am Geriatr Soc. 2021. PMID: 33432578. doi:10.1111/jgs.17013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。